Drugs / PL-3994
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04318145 | Nov 2020 → Dec 2023 | diastolic heart failure | Palatin Technologies, Inc | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00686803 | Apr → Jul 2008 | hypertensive disorder | Palatin Technologies, Inc | Completed | No outcome recorded |
| Phase 2 | NCT01304628 | — | asthma | Palatin Technologies, Inc | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2015-09-28 | Palatin Technologies, Inc | Results Preclinical Data on PL-3994 for Heart Failure and Resistant Hypertension Presented at 2015 Heart Failure Society of America Annual Meeting palatin.com ↗
The data presented demonstrated that corin and cardiac natriuretic peptides play an important role in regulating cardiac hypertrophy and fibrosis, and that treatment with PL-3994 significantly reduced cardiac hypertrophy and pro-fibrotic and inflammatory gene activation. |
| 2011-03-03 | Palatin Technologies, Inc | Regulatory FDA Clears Palatin Technologies’ IND Filing to Commence Clinical Studies for Asthma palatin.com ↗
Palatin Technologies, Inc. (NYSE Amex: PTN ) today announced that the U.S. Food and Drug Administration (FDA) has cleared Palatin’s request to begin a Phase 2A proof-of-concept human trial under an Investigational New Drug (IND) application using a subcutaneously administered formulation of PL-3994, an NPR-A agonist compound, in development for treatment of acute exacerbations of asthma. |
| 2010-06-21 | Palatin Technologies, Inc | Results Palatin Technologies, Inc. Announces Positive Preclinical Data with PL-3994 for Asthma Indications palatin.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-09-28 | Palatin Technologies, Inc | Preclinical Data on PL-3994 for Heart Failure and Resistant Hypertension Presented at 2015 Heart Failure Society of America Annual Meeting palatin.com ↗ |
| 2011-06-21 | Palatin Technologies, Inc | Palatin Technologies, Inc. Issued U.S. Patent for Key Component in PL-3994 Drug Candidate palatin.com ↗ |
| 2011-03-03 | Palatin Technologies, Inc | FDA Clears Palatin Technologies’ IND Filing to Commence Clinical Studies for Asthma palatin.com ↗ |
| 2010-06-21 | Palatin Technologies, Inc | Palatin Technologies, Inc. Announces Positive Preclinical Data with PL-3994 for Asthma Indications palatin.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PL-3994 | “The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of subcutaneous (SC) PL-3994, relative to placebo in subjects with controlled hypertension.” NCT00686803 ↗ |
| Action | Activate | “Atrial natriuretic peptide receptor A agonist” CHEMBL4297320 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4297320 ↗ |
| Route | Subcutaneous | “subcutaneous (SC) PL-3994” NCT00686803 ↗ |
| Target | NPR1 | “Atrial natriuretic peptide receptor A agonist” CHEMBL4297320 ↗ |